TriangleOPT-821 (QS-21) (NCT06057948)
OPT-821 (QS-21) trial for Neuroblastoma (NCT06057948). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people with high-risk neuroblastoma in complete remission. First remission requires at least six months since anti-GD2 immunotherapy began; second or later remissions also qualify.
The idea: compare two oral beta-glucan schedules alongside ten vaccine doses. The OPT-821 adjuvant aims to boost vaccine immune responses; beta-glucan can prime immune cells. Repeated fourteen-day courses continue until about week twenty or fifty-two, then accompany later vaccinations. Researchers measure anti-GD2 antibody levels.
This phase 2 study plans 100 patients. Brian Kushner leads at Memorial Sloan Kettering, New York; seven US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.